Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: grading of evidence: evidence to recommendation tables, first issued 7 May 2021, updated 28 October 2021, last updated 15 March 2022